- 1
- 2
Consulate General of Canada in Shanghai
Lulu Mi
Life Sciences Trade CommissionerCredevo Pte. Ltd.
DIMITAR DIMITROV
Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET
InvivoSciences Inc.
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.
Ayla Annac
CEOLansen Pharmaceutical Holdings Limited
Dong Sheng
BD ManagerNeuroZone
In particular, we have developed pathology-specific platforms to generate rapid and informative data on efficacy, toxicity, metabolism and mechanism of action, supported by proprietary technologies such as MicroTISSUE (dissecting microenvironment-cell interaction in complex inflammatory scenarios) or MITOS (a comprehensive analytical platform for quantitative analysis of mitochondrial function ).
Our approach enables effective selection and ranking of the most promising candidates per indication.
Moreover, we profile candidates at different level of complexity starting from:
a) pharmacology profiling (GPCR; Ion Channel receptors)
b) identification of biochemical pathways responsible for therapeutic efficacy (transcriptomics)
c) disease modified barrier permeability (BBB and endothelial)
Fabio Bianco
PresidentReistone Biopharma
Currently we are looking for either partnership to develop the AD and/or UC or CD indications for phase 3 or out-license the global right excluding China market.
Paul Chen
Chief of StaffSichuan Kelun-Biotech Biopharmaceutical Co., Ltd
Kelun-Biotech Biopharmaceutical is a subsidiary of Kelun Pharmaceutical Group established in 2016
Looking for antibody and samall molecular out-license and in-license
Chunlin Li
BD btlichl@kelun.comSimcere Pharmaceutical Group
We are rapidly transitioning to an innovation and R&D driven Pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today' s patients with medicines of the future“ We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” 1 and “Top 100 Pharmaceutical Manufacturing Enterprises of China”